As of mid-2015, BG Medicine (BGMD) has made the distinct transition from being a research & development company to being a “commercial diagnostics company”. When taking into account BG’s worldwide license, development and commercialization agreements with Abbott . . .
Trades Are Ordered by Date Updated
Bought at 3.32 and 3.19 with an average PPS of $3.25. Stock broke out end of day. Looking for bullish continuation tomorrow and exit at $4.30.
Rules for investing in Chinese companies listed on the Hong Kong Stock Exchange were recently eased for investors within China. The change triggered a round of buying that send ETFs that track the Chinese market into parabolic rallies. However, this is probably not a great thing for many Chinese . . .
Looking for 1% profit after move past high of 24.93 from yesterday.